Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as zodasiran Injection
zodasiran · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Zodasiran | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | Calculated volume to match active treatment by sc injection (randomized period). 4 or 5 doses of zodasiran by sc injection (optional open-label period) |
| Name | Type | Description |
|---|---|---|
| Zodasiran | DRUG | By sc injection |
| zodasiran Injection | DRUG | ARO-ANG3 Injection |
| Placebo | DRUG | sterile normal saline (0.9% NaCl) |
Inclusion Criteria: * Adolescents 12 to \<18 years of age who are nonpregnant, nonlactating, and do not plan to become pregnant during the study * Body weight ≥35 kilograms (kg) at screening * HoFH based on a supportive genetic test (from a source-verifiable medical record or based on screening gen...
Zodasiran is an investigational small molecule being developed for homozygous familial hypercholesterolemia, a genetic condition causing severely elevated cholesterol levels. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
Zodasiran is a small interfering RNA (siRNA) therapeutic, classified under the -siran target class. It is designed to reduce the production of a protein involved in cholesterol metabolism, thereby lowering cholesterol levels in patients with homozygous familial hypercholesterolemia.
Zodasiran is being developed by Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol ARWR. The company is conducting Phase 3 clinical trials to evaluate the drug's safety and efficacy.
Zodasiran is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied in clinical trials to assess its safety and effectiveness for treating homozygous familial hypercholesterolemia.
Zodasiran is being evaluated in two Phase 3 trials: NCT07037771, a study in adolescent and adult subjects with homozygous familial hypercholesterolemia, and NCT07473843, a study in adolescent participants with the same condition. Both trials are randomized, double-blind, and placebo-controlled.
Yes, zodasiran is also known as zodasiran Injection. Both names refer to the same investigational drug being developed by Arrowhead Pharmaceuticals for the treatment of homozygous familial hypercholesterolemia.